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Abstract: 3,4-Methylenedioxymethamphetamine (MDMA) is an illicit psychoactive drug
with cardiovascular effects that have not been fully described. In the current study, we
observed the effects of acute MDMA on rabbit left ventricular function. We also observed
the effects of MDMA on nuclear factor-kappa B (NF-B) activity in cultured rat
ventricular myocytes (H9c2). In the rabbit, MDMA (2 mg/kg) alone caused a significant
increase in heart rate and a significant decrease in the duration of the cardiac cycle.
Inhibition of nitric oxide synthase (NOS) by pretreatment with L-NAME (10 mg/kg) alone
caused significant dysfunction in heart rate, systolic pressure, diastolic pressure, duration
of relaxation, duration of cardiac cycle, and mean left ventricular pressure. Pretreatment
with L-NAME followed by treatment with MDMA caused significant dysfunction in
additional parameters that were not abnormal upon exposure to either compound in
isolation: duration of contraction, inotropy, and pulse pressure. Exposure to 1.0 mM
MDMA for 6 h or 2.0 M MDMA for 12 h caused increased nuclear localization of NF-B
in cultured H9c2 cells. The current results suggest that MDMA is acutely detrimental to
heart function and that an intact cardiovascular NOS system is important to help mitigate
early sequelae in some functional parameters. The delayed timing of NF-B activation
suggests that this factor may be relevant to MDMA induced cardiomyopathy of later onset.
Keywords: MDMA; ecstasy; NF-kB; nuclear; iNOS; H9c2; cardiac myocytes; rabbit
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1. Introduction
3,4-Methylenedioxymethamphetamine (MDMA) is a widely used recreational drug among teens
and young adults. This substance has molecular similarities to amphetamine and mescaline [1].
Unsurprisingly, users of MDMA report subjective effects attributable to both compounds [1].
Although the physiological impact of this drug has yet to be fully characterized, and exact mechanistic
details are still being elucidated, the growing body of evidence continues to support the theory that
MDMA abuse is detrimental to the cardiovascular system [1–10].
In humans, MDMA use can cause abnormal increases in heart rate, mean arterial pressure, and
myocardial wall stress [2]. In rats, binge pattern intravenous administration of MDMA (9 mg/kg)
induces profound and progressive bradycardia with accompanying hypotension [3]. There is evidence
that MDMA may directly affect heart function by prolonging Purkinje fiber action potential duration
[7]. Other evidence suggests that systemic effects in the form of autonomic dysregulation may be more
important in the rhythmic and pressor abnormalities seen with MDMA abuse [4,10]. This may involve
increased net release of norepinephrine and alpha-adrenergic receptor interaction [1,4,5,9]. In addition,
abnormally elevated intracellular calcium, as observed in our own previous experiments with MDMA,
may lead to further complications including myocardial hypertrophy, fibrosis, and apoptosis [8,11,12].
The direct mechanism(s) by which MDMA causes adverse cardiovascular effects is still under
investigation. In cardiac myocytes, one important transcription factor activated by MDMA is nuclear
factor-kappa B (NF-B) [11]. NF-B is ubiquitously found in a wide variety of cell types as a
heterodimer consisting of p50 and p65 subunits [13–16]. Under normal conditions, NF-B is localized
mainly in the cytoplasm where it is inhibited by the I-kappa B () family of regulatory proteins [17].
Activation occurs when B becomes phosphorylated, ubiquitinated, and subsequently degraded
allowing for translocation into the nucleus where NF-B binds to B-response elements in the
promoter/enhancer regions of various genes [13,18–23]. This process upregulates the expression of
various downstream inflammatory factors including cytokines, chemotactic proteins, and cellular
adhesion molecules [23]. There are several well known inducers of NF-B including interleukin-1
(IL-1, interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor- (TNF-),
lipopolysaccharide (LPS), physical trauma, ionizing radiation, and free radicals [24–28]. Previous
studies in our laboratory indicate that illicit drugs such as cocaine can also activate this transcription
factor [11,29].
In the heart, NF-B activation is closely associated with pro-inflammatory as well as anti-apoptotic
conditions. Rat cardiac myocytes in culture exposed to an oxidizing environment, such as
co-incubation with hydrogen peroxide, show an increased NF-B activity [30]. Myocardial
intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) gene
expression are effectively reduced when NF-B is inhibited [31,32]. These cell surface proteins are
important in mediating inflammatory cell recruitment and infiltration by acting as counter-receptors for
circulating monocyte and lymphocyte integrins [32]. The anti-apoptotic nature of NF-B has been
demonstrated in primary cultures of rat ventricular myocytes. In these cells, TNF- induced apoptosis
is significantly enhanced by NF-B inhibition [33].
Earlier research reveals important information concerning the effects of MDMA on redox balance
within the cell, a critical aspect in NF-B regulation. MDMA has been shown to simultaneously
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increase reactive oxygen species (ROS) production and deplete reduced glutathione levels in hepatic
stellate cells [34]. MDMA also increases hydroxyl radical formation in the rat brain [35].
Theoretically, the oxidative stress created by MDMA in these studies can promote NF-B activation,
modulate downstream genetic expression, and induce an inflammatory response. Supporting evidence
exists in rats given binge-pattern administration of MDMA over the course of several weeks [3,36].
These animals show histological signs of increased lymphocyte infiltration and inflammatory damage
to the myocardium [3]. They also display significantly elevated nitrotyrosine content of proteins (an
index of ROS activity) isolated from the left ventricle [36].
We have reported that NF-B is activated by MDMA in a dose-dependent manner [11]. By way of
genetic array technology, we have also observed that several NF-B dependent genes are upregulated
at the transcriptional level. Some of these genes, such as PCNA, Cox-2, and VCAM-1 have been
implicated in cardiac disease states such as heart failure, hyperplasia, fibrosis and inflammation
[32,37,38]. Others, such as Gadd45 and RAD23A, are involved with survival and compensatory
responses [39,40]. While genes, such as inducible nitric oxide synthase (iNOS) and brain natriuretic
peptide (BNP) are upregulated in heart failure, but were not significantly modulated in response to
MDMA under our conditions. It is possible that iNOS and BNP were affected at earlier time
points [41,42].
iNOS is an important signaling molecule in the cardiovascular system and is under NF-B control
[41]. The metabolic end product of the enzyme - nitric oxide (NO) is a well known vasodilator and
helps to regulate blood pressure [43–45]. In the compromised endothelium, as commonly seen in
atherosclerosis, NO output is significantly diminished [46,47]. Atherosclerosis has aberrant functional
consequences for the heart such as increased vasoconstriction and elevations in heart rate and
contractility (inotropy) that may be exacerbated by MDMA use.
The full scope of MDMA induced effects on the cardiovascular system and the extent of NF-B
involvement remains incompletely characterized. Therefore, the purpose of the current study was to
observe the cardiac functional response to acute MDMA administration in the intact rabbit and to
further characterize molecular events in cultured ventricular myocytes as a result of direct MDMA
exposure. We also observed the effects of MDMA on nitric oxide synthase inhibition in the
cardiovascular system.
2. Materials and Methods
2.1. In Vivo Experiments
Sixteen adult New Zealand White (NZW) rabbits (Oryctolagus cuniculus) were randomly divided
into 3 treatment groups: Placebo (n = 5), MDMA (n = 7), and L-NAME + MDMA (n = 4). A
Digi-Med Heart Performance Analyzer- model 410 (Micro-Med; Tustin, CA) was used to measure
left ventricular systolic pressure (MaxP), diastolic pressure (EDP), inotropy (dP/dt), lusitropy
(NdP/dt), duration of contraction (DCON), duration of 1/2 relaxation (1/2R), and heart rate (HR).
From these parameters, three additional parameters were calculated: duration of cardiac cycle
(CCycle), mean ventricular pressure (MeanP), and pulse pressure (PulseP). The analyzer was
connected to a Millar model SPR-524 catheter (Millar Instruments, Inc.) which contains a specialized
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sensor tip designed for transducing mechanical signals directly from within the left ventricular
chamber into electrical signals that can be interpreted by the analyzer and recorded by the computer.
Animals were placed under a surgical plane of anesthesia by administering ketamine (40 mg/kg)
and xylazine (5 mg/kg) intramuscularly. A 2 cm longitudinal mid-line incision was made parallel to
the trachea. The left common carotid artery was carefully isolated from the surrounding tissues and a
Millar catheter gently inserted into the left ventricle. A 24 G ½ inch catheter was inserted into the
marginal ear vein of the rabbit for the injection of all drugs and solutions. Animals in the placebo
group were given 0.9% sterile isotonic saline intravenously (IV). Animals in the MDMA group
received 2 mg/kg MDMA IV bolus. Animals in the L-NAME + MDMA group were pretreated with
10 mg/kg L-NAME (non-specific NOS inhibitor) 10 min before 2 mg/kg MDMA was injected, IV.
Left ventricular functional data was recorded every 10 s by the computer during the entire experiment.
After data collection, the animal was euthanized and the heart was carefully removed and weighed on
an analytical balance. The left ventricle was separated from all other tissue, snap-frozen with liquid
nitrogen, and stored at −80 °C until analysis. All functional data were normalized to
baseline/pre-injection parameters and statistically analyzed as ratiometric units using single-factor
ANOVA for each time point. The functional effects of L-NAME alone relative to pre-injection were
analyzed via paired t-test.
2.2. In Vitro Experiments
2.2.1. Reactive Oxygen Species Assay
These experiments were designed to measure the effects of MDMA on reactive oxygen species
(ROS) generation in cultured cardiac myocytes. H9c2 cells (Rattus norvegicus) were grown to 85–90%
confluency in T-75 flasks at 37 °C and 5% atmospheric CO2 (incubator controlled). Culture media
consisted of 15 mL Dulbecco’s Modified Eagle’s Medium™ containing 10% fetal bovine serum
(FBS). Cells and media were purchased from American Type Culture Collection (ATCC; Manassas,
VA, USA). Cell manipulations were carried out under a tissue culture hood using aseptic technique.
The green fluorescent indicator 2’,7’-dichlorofluorescin diacetate (Molecular Probes) was used to
measure the presence of MDMA induced ROS generation. On day 1, with the aid of a hemacytometer,
approximately 150,000 H9c2 cells (approximately 1.05 × 105 cells/cm2) were plated onto a sterile
multi-well culture plate (Corning). The cells were then returned to the incubator for 24 hours.
On day 2, the overlying media was removed and discarded. The cells were washed with 1 mL of
Hank’s Media (ATCC) in order to remove residual cell culture media which contained a red coloring
that might interfere with the indicator. Afterward, 1 mL of fresh Hank’s Media was placed in each
well. 2’,7’-dichlorofluorescin diacetate was dissolved in dimethyl sulfoxide (DMSO) (Sigma). To load
the cells, 1 mL of the 5% indicator solution was added to each well and the culture plate was gently
swirled for 1 min. The culture plate was then wrapped in aluminum foil and returned to the incubator
for 30 min.
Following the loading period, the cells were washed twice with 1 mL of Hank’s Media. Next, 2 mL
of fresh Hank's Media was placed into each well and the plate was returned to the incubator for 30 min
prior to drug administration. The following concentrations of MDMA were tested: 1 × 10−4 M,
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1 × 10−3 M, and 1 × 10−2 M. The drug was dissolved in Hank's Media and 2 mL of each concentration
was gently added to the appropriate wells. Each well served as its own 0 M control. The cells were
imaged using a Zeiss model 510 LSM confocal microscope (Carl Zeiss) equipped with a variable
wavelength argon laser, epifluorescent filters, and a digital camera. Cells generating ROS exhibited a
quantifiable green fluorescence. Images were captured 2 and 5 min after drug exposure and then
analyzed by the program Metamorph (Universal Imaging) for densitometry. The results were exported
to Excel (Microsoft) and statistically analyzed using paired t-test.
2.2.2. ELISA for NF-B
These experiments were designed to determine the effect of MDMA on the degree of NF-B
activation in cultured cardiac myocytes. H9c2 cells were grown and maintained as previously
described in our ROS experiments. On day 1 of the experiment, approximately 1 × 106 cells were
plated onto each well of a sterile 6-well culture plate (approximately 1.05 × 105 cells/cm2) and returned
to the incubator for 24 hours. On day 2, the cells were stimulated with MDMA or placebo (culture
media). Two concentrations of MDMA were used: 1.0 mM or 2.0 M. To stimulate the cells, the drug
was dissolved in an appropriate volume of cell culture media and 5 mL of total solution added to each
well. An equal volume of cell culture media (without drug) was added to cells that served as our paired
controls (0 mM MDMA). The cells were then returned to the incubator for either 3, 6, or 12 h. These
concentrations and exposure times were specifically chosen because of evidence in human subjects
suggesting that peak MDMA plasma levels occur between 2–4 h after drug administration [48]. Each
time point and drug concentration was tested independently in separate experiments.
At the end of the drug exposure period, nuclear extracts were obtained per manufacturer
instructions using an extraction kit (AY2002) from Panomics (Fremont, CA). Briefly, the cells were
washed twice with 10 mL of isotonic phosphate buffered saline (PBS), pH 7.4. Cells were lysed using
a lysis buffer (1 mL solution of 10 mM HEPES, 10 mM KCl, 10 mM EDTA; 10 L of 100 mM DTT;
10 L protease inhibitor cocktail; 40 L of 10% IGEPAL) for 10 min. The cells in each well were then
scraped and transferred to a separate 1.5 mL tube and centrifuged at 14,000 × g for 3 min at 4 °C. The
pellets were retained and placed on ice.
A separation buffer (147 L solution of 20 mM HEPES, 0.4 M NaCl, 1 mM EDTA, 50% glycerol;
1.5 L protease inhibitor cocktail; 1.5 L of 100 mM DTT) was used to isolate nuclear proteins. The
pellets were resuspended in the separation buffer and gently agitated on ice for 2 h. The nuclear
extracts were stored at −80 °C in sterile nuclease-free microcentrifuge tubes until analysis. A
quantitative assay (Bradford) was used to determine the total protein concentration of each sample.
To measure the presence of activated NF-B in the nuclear extracts, a modified ELISA based kit
(EK1010) from Panomics (Fremont, CA) was used. A specialized 96 well microplate pre-coated with
NF-B binding consensus oligonucleotide was incubated with 2.0 g of total nuclear extract. Primary
antibody to the p50 subunit of NF-B was added to each well at a dilution of 1:100. Conjugated
secondary antibody was added to each well at a dilution of 1:1000. Colorimetric substrate was added
and the reaction allowed to incubate at room temperature for 15 min. The plate was then analyzed at
A450 nm using a FluoStar™ spectrophotometric microplate reader (BMG Labtech, Inc. Durham, NC).
The results were exported to Excel (Microsoft) and statistically analyzed using the paired t-test.
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In order to test for NF-B activity in left ventricular heart tissues of acutely treated rabbits, another
set of experiments was performed. Nuclear extracts were obtained per manufacturer instructions using
an extraction kit (AY2002) from Panomics (Fremont, CA). A quantitative assay (Bradford) was used
to determine the total protein concentration of each sample.
To measure the presence of activated NF-B in the nuclear extracts, a modified ELISA based kit
(P/N 12490) from Panomics (Fremont, CA) was used. A specialized 96 well microplate pre-coated
with streptavidin was incubated with a mixture containing 10.0 L binding buffer, 2.5 L NF-B
specific biotinylated oligonucleotide probe, and 1.0 g of total nuclear extract. Primary antibody to the
p50 subunit of NF-B was added to each well at a dilution of 1:200. Conjugated secondary antibody
was added to each well at a dilution of 1:200. Colorimetric substrate was added and the reaction was
allowed to incubate at room temperature for 15 min. The plate was then analyzed as previously
described. The results were exported to Excel (Microsoft) and statistically analyzed using the
two-sample t-test.
3. Results
3.1. In Vivo Experiments
Analysis of left ventricular mechanical function revealed that MDMA alone significantly increased
heart rate 5 min after injection (Figure 1) and decreased the duration of the cardiac cycle at the 15 min
time point (Figure 2). The elevation in heart rate persisted throughout the remainder of post-injection
monitoring. No significant changes in any of the other functional parameters were observed in the
MDMA treated group relative to the Placebo group.
In the group of animals pretreated with L-NAME and then given MDMA (L-NAME + MDMA),
heart rate (Figure 1) was significantly decreased while systolic and diastolic pressures, duration of
contraction, duration of relaxation, duration of cardiac cycle, mean pressure, and pulse pressure were
all significantly elevated from baseline (Figures 2–9). dP/dt showed a significant increase relative to
the MDMA group at the 1 min mark.
L-NAME alone significantly decreased heart rate, but elevated systolic pressure, diastolic pressure,
duration of relaxation, duration of cardiac cycle, and mean pressure (Figure 10). DCON, dP/dt, and
PulseP were not significantly affected by L-NAME alone. However, after the addition of MDMA,
these parameters were significantly increased.
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Figure 1. Normalized heart rate (mean ± SD). Placebo group (n = 5) received sterile
isotonic saline. MDMA group (n = 7) received 2 mg/kg MDMA. L-NAME + MDMA
group (n = 4) received 10 mg/kg L-NAME for 10 min followed by 2 mg/kg MDMA.
* p < 0.05 compared to Placebo. ^ p < 0.05 compared to MDMA.

.

1.4

Normalized Beats Per Min

Heart Rate

1.2

*

*

1

^
*

0.8

^
*

^
*

1 min
5 min

0.6

15 min

0.4
0.2
0
Placebo

MDMA

L-NAME+MDMA

Figure 2. Normalized systolic pressure (mean ±SD). Placebo group (n = 5) received sterile
isotonic saline. MDMA group (n = 7) received 2 mg/kg MDMA.
L-NAME + MDMA group (n = 4) received 10 mg/kg L-NAME for 10 minutes followed
by 2 mg/kg MDMA. * p < 0.05 compared to Placebo. ^ p < 0.05 compared to MDMA.
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Figure 3. Normalized diastolic pressure (mean ± SD). Placebo group (n = 5) received
sterile isotonic saline. MDMA group (n = 7) received 2 mg/kg MDMA.
L-NAME + MDMA group (n = 4) received 10 mg/kg L-NAME for 10 minutes followed
by 2 mg/kg MDMA. * p < 0.05 compared to Placebo. ^ p < 0.05 compared to MDMA.
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Figure 4. Normalized duration of contraction (mean ± SD). Placebo group (n = 5) received
sterile isotonic saline. MDMA group (n = 7) received 2 mg/kg MDMA.
L-NAME + MDMA group (n = 4) received 10 mg/kg L-NAME for 10 minutes followed
by 2 mg/kg MDMA. * p < 0.05 compared to Placebo. ^ p < 0.05 compared to MDMA.
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Figure 5. Normalized duration of relaxation (mean ± SD). Placebo group (n = 5) received
sterile isotonic saline. MDMA group (n = 7) received 2 mg/kg MDMA.
L-NAME + MDMA group (n = 4) received 10 mg/kg L-NAME for 10 minutes followed
by 2 mg/kg MDMA. * p < 0.05 compared to Placebo. ^ p < 0.05 compared to MDMA.
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Figure 6. Normalized duration of cardiac cycle (mean ± SD). Placebo group (n = 5)
received sterile isotonic saline. MDMA group (n = 7) received 2 mg/kg MDMA.
L-NAME + MDMA group (n = 4) received 10 mg/kg L-NAME for 10 min followed by
2 mg/kg MDMA. * p < 0.05 compared to Placebo. ^ p < 0.05 compared to MDMA.
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Figure 7. Normalized mean pressure (mean ± SD). Placebo group (n = 5) received sterile
isotonic saline. MDMA group (n = 7) received 2 mg/kg MDMA. L-NAME + MDMA
group (n = 4) received 10 mg/kg L-NAME for 10 minutes followed by 2 mg/kg MDMA.
* p < 0.05 compared to Placebo. ^ p < 0.05 compared to MDMA.
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Figure 8. Normalized pulse pressure (mean ± SD). Placebo group (n = 5) received sterile
isotonic saline. MDMA group (n = 7) received 2 mg/kg MDMA. L-NAME + MDMA
group (n = 4) received 10 mg/kg L-NAME for 10 minutes followed by 2 mg/kg MDMA.
* p < 0.05 compared to Placebo. ^ p < 0.05 compared to MDMA.
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Figure 9. Normalized dP/dt (mean ± SD). Placebo group (n = 5) received sterile isotonic
saline. MDMA group (n = 7) received 2 mg/kg MDMA. L-NAME + MDMA group (n = 4)
received 10 mg/kg L-NAME for 10 minutes followed by 2 mg/kg MDMA. ^ p < 0.05
compared to MDMA.
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Figure 10. Effects of L-NAME on cardiac functional parameters (mean ± SD).
L-NAME + MDMA group (n = 4). Pre-injection parameters were record for 15 minutes.
Post-injection of 10 mg/kg L-NAME was recorded for 10 minutes. * p < 0.05 compared to
pre-injection.
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3.2. In Vitro Experiments
3.2.1. Reactive Oxygen Species Assay
Using cultured H9c2 cells, we observed a significant increase in ROS generation in response to
MDMA exposure. ROS generation was significantly elevated relative to 0 M control 5 min after
exposure to 1 × 10−2 M MDMA (Figure 11).
Figure 11. ROS assay signal intensity at 5 min (mean ± SD). Each well served as its own
control (n = 3). * p < 0.05 compared to Control Signal.
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3.2.2. ELISA for NF-B
We observed a significant increase in nuclear localization of NF-B in H9c2 cells exposed to
1.0 mM MDMA at the 6 h time point (Figure 12). Measurements taken at the 3 h and 12 h time points
for cells exposed to 1 mM MDMA were not significantly different from their paired controls. We also
observed significant nuclear localization of NF-B with the 2.0 M dose, however this occurred at the
12 h time point (Figure 13). In addition, we did not observe a significant difference in NF-B activity
between the placebo and MDMA groups in myocardial tissue specimens from our functional
experiments (data not shown).

Int. J. Mol. Sci. 2010, 11
Figure 12. ELISA for NF-B nuclear localization (mean ± SD). Either 0 mM MDMA
(media only) (n = 3) or 1 mM MDMA (n = 3) was used at each time point. Each
experiment was performed independently. A kit-provided assay-level positive control
(+Control) of nuclear extracts prepared from IL-1 treated HeLa cells was included during
the plate run. * p < 0.05.

Figure 13. ELISA for NF-B nuclear localization (mean ± SD). Either 0 M MDMA
(media only) (n = 3) or 2 M MDMA (n = 3) was used at each time point. Each
experiment was performed independently. A kit-provided assay-level positive control
(+Control) of nuclear extracts prepared from IL-1 treated HeLa cells was included during
the plate run. * p < 0.05.
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4. Discussion
4.1. Effects of MDMA
In this study we further characterize the effects of MDMA on the cardiovascular system. The
widespread abuse of MDMA, along with the possibility of direct and indirect effects contributing to
both acute and long-term sequelae, makes this drug particularly important in terms of potential
cardiotoxicity. We show, in the intact rabbit, that MDMA can cause acute functional abnormalities of
the left ventricle and that NOS signaling may be an important protective response. We also show, in
cultured cardiac myocytes, that MDMA has the potential to activate NF-B, a key molecular
transcription factor associated with myocardial pathology. The current findings support earlier reports
that implicate MDMA in augmenting both sympathetic responses and NF-B activity [1–5,9,10].
Compared to placebo, MDMA alone caused a 21% increase in heart rate 15 min after injection and
significantly decreased the duration of the cardiac cycle at the same time point (17%). Due to the early
onset of the cardiovascular responses, and the fact that NF-B activation in our cultured cardiac
myocytes was not observed at or before the 3 h time point with either MDMA dose, these responses
may not be the result of interaction with the myocardial NF-B pathway. Two possibilities may
explain these results. The injected MDMA may have directly and rapidly affected cardiovascular
calcium homeostasis in blood vessels and led to the slight increase in systolic and diastolic pressures.
This is unlikely, however, because the changes in pressures were slight and non-significant. It is
possible that MDMA may have stimulated systemic sympathetic activity by causing a net increase in
epinephrine and norepinephrine release from central stores and/or peripheral nerve endings. This idea
is supported by the fact that there was a significant increase in heart rate 5 and 15 min after MDMA
injection and suggests a possible direct effect of MDMA on the sinoatrial node of the heart or indirect
stimulation via catecholamines.
Previously, we have demonstrated that MDMA causes a significant increase in intracellular calcium
in cultured H9c2 cells within a few minutes of drug administration [11]. Elevated calcium levels may
affect intracellular signaling pathways leading to diverse pathological responses including fibrosis and
hypertrophy. Disruptions in calcium homeostasis may also alter myocardial excitability and
contractility, which may induce ventricular arrhythmia and other more immediate functional
abnormalities such as the increased heart rate and decreased cardiac cycle duration observed in the
present study. An increase in heart rate associated with a decrease in the duration of the cardiac cycle
may suggest that filling and ejection of blood in the heart exposed to MDMA may be acutely
compromised.
In cultured H9c2 heart cells, a significant increase in ROS generation was observed 5 min after
1 × 10−2 M MDMA exposure. Although we exposed the H9c2 heart cells to MDMA acutely and
measured ROS generation 5 min later, the half-life of MDMA has been reported to be approximately
9 ± 2.2 h [49]. In addition, there is evidence that MDMA metabolites adversely affect cardiac myocyte
redox balance [6]. MDMA is metabolized into toxic metabolites including HMMA, MDA, and HMA,
and may lead to the formation of peroxinitrite, all of which may prolong and exacerbate the deleterious
effects of the drug [50–52]. In vivo and in vitro studies provide evidence supporting the role of both
excessive monoamine release and oxidative stress in cardiovascular conditions (such as ischemia-
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reperfusion injury, hypertension, catecholamine-induced cardiomyopathy, and heart failure) that lead
to cardiovascular dysfunction [53–55]. In addition to generation of ROS, 1.0 mM of MDMA also
significantly increased the activity of NF-B in H9c2 heart cells in culture after 6 h of exposure. After
12 h of exposure, 2.0 M MDMA significantly enhanced NF-B activity. This redox sensitive
transcription factor is known to upregulate the expression of genes associated with myocardial
inflammation, hypertrophy, and fibrotic scar formation.
Preliminary evidence from our lab indicates that NF-B is not significantly activated in H9c2 cells
exposed to MDMA for less than 3 h (data not shown). It is possible that under the current experimental
conditions 3 h is not sufficient time for significant nuclear accumulation of this transcription factor.
Based upon our previous investigation [11], a biphasic response to 1.0 mM MDMA is suggested since
sometime after 6 h, nuclear presence of NF-B becomes significantly degraded, but then reappears at
the 24 h time point according to our genetic reporter study. It is uncertain why this drug is associated
with a temporal response with regard to NF-B. It is possible that some metabolic by-product of
MDMA may be participating later in the NF-B response and/or cellular adaptation is occurring in
response to the persistent presence of metabolites over extended periods of time.
Significant NF-B activity was absent in the myocardial tissue samples from our functional
experiments. Since the animals were exposed to MDMA for only 15 min prior to euthanasia and tissue
harvesting, the lack of NF-B activity is in agreement with our cell culture findings within the same
timeframe. Therefore, it is unlikely that any of the acute functional responses induced by MDMA are
due to the activation of myocardial NF-B and the consequent expression of downstream dependent
genes such as inflammatory cytokines and adhesion molecules. It is more likely that other tissues, such
as the vasculature and/or sympathetic peripheral nerve endings may be responsive to this drug within
the tested timeframe and may contribute to the abnormal functional findings in the left ventricle by
increasing peripheral resistance. Another possibility is that MDMA induced ROS generation, as
observed in the current study, and abnormal intracellular Ca2+ elevation, as observed in our previous
study [11], presents a more immediate threat to normal cardiac function since these events were
precipitated rapidly after drug exposure.
4.2. MDMA and L-NAME
Since MDMA activates NF-B, we predicted that downstream dependent genes such as inducible
nitric oxide synthase (iNOS) would be upregulated as a result of MDMA exposure. iNOS is a
cardioprotective enzyme closely associated with compensatory actions in the heart during ischemic
preconditioning and inflammatory cytokine exposure [56,57]. It is possible that MDMA stresses the
heart and causes the myocardium to respond in an adaptive manner by increasing the synthesis of this
enzyme. In the current study, we performed an independent series of in vitro experiments in which we
again exposed H9c2 heart cells in culture to 2.0 M and 1.0 mM concentrations of MDMA. We did
not observe a significant change in the expression of iNOS at the protein level. Since iNOS expression
in cardiac myocytes is NF-B dependent, it is still possible that a certain degree of iNOS expression
occurred below the threshold for detection, or at time points earlier than we examined.
The importance of an intact nitric oxide signaling system in reducing the adverse functional effects
of MDMA is readily apparent in our functional experiments. L-NAME is a well characterized inhibitor
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of the major NOS isoforms [58,59]. In the rat, this compound induces a dose-dependent increase in
heart rate and mean arterial pressure [58]. L-NAME also decreases blood flow by increasing
vasoconstriction in several vascular beds including those associated with the kidneys, mesenteries, and
hindquarters [60]. Endothelial NOS (eNOS) is particularly important to normal cardiovascular
function. In mice, decreased expression of eNOS reduces vasorelaxation capacity and increases arterial
pressure [61].
In our experiments, injection of L-NAME alone caused a significant increase in heart rate, left
ventricular systolic and diastolic pressures, the duration of left ventricular relaxation and the duration
of the cardiac cycle. When the animal was given MDMA alone, heart rate increased and the duration
of the cardiac cycle decreased. These results are consistent with what was expected since the duration
of the cardiac cycle is inversely proportional to the heart rate. In the presence of L-NAME, MDMA
decreased heart rate and increased the duration of the cardiac cycle. These results may suggest that one
mechanism used by MDMA to alter heart function is via the nitric oxide synthase pathway. Nitric
oxide has been shown to play a role in the modulation of sympathetic nerve activity and baroreflex
sensitivity [62]. For instance, if MDMA and L-NAME are both sympathomimetic synergists, then the
increased systolic pressure induced by L-NAME may be enhanced by the addition of MDMA. The
consequent decrease in heart rate may be exclusively due to the effects of L-NAME or the
compensatory baroreceptor reflexes of the intact cardiovascular system responding to the slight change
in pressure. It is therefore not possible, in this model, to separate the reflex component of the response
to these drugs.
The use of MDMA may have important implications for individuals with a compromised vascular
endothelium, as seen in atherosclerosis. Endothelial cells are an important source of nitric oxide which
helps to maintain normal blood pressure by regulating vascular diameters and peripheral resistance.
Therefore, users of MDMA with extensive atherosclerotic lesions may be at increased risk for the
development of acute rhythmic abnormalities and subsequent heart failure.
5. Conclusions
This study provides evidence that MDMA is acutely detrimental to normal heart function. The
current evidence also suggests that an intact cardiovascular NOS system exerts a partially protective
response to the drug in some, but not all, functional parameters. It is likely that MDMA induced
autonomic dysregulation contributes to the functional abnormalities we observed and that these effects
are characteristic of the immediate/early consequences of abuse. In addition, MDMA may be toxic to
the myocardium due to its ability to increase ROS generation and activate NF-B. However, since the
NF-B response was significantly elevated in vitro only after several hours past initial exposure and
not elevated in vivo during the timeframe of our functional studies, the acute detrimental effects of
MDMA on heart function may not be related to myocardial activation of this transcription factor.
Nevertheless, it remains possible that sequelae of latter onset may be caused by NF-B activation and
the expression of genes under its control. Further investigations involving MDMA and the effects of
various patterns and durations of drug exposure will yield important additional information as to the
true nature of this substance and its impact on the cardiovascular system.
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